Which “pembrolizumab” patents are we talking about?
“Pembrolizumab” has multiple overlapping patents covering different things (drug substance, formulation, manufacturing/process, and specific uses). So “expiration” depends on which patent family and which country you mean, and a complete answer typically needs a patent-by-patent (or family-by-family) breakdown rather than a single date.
What dates can be checked for pembrolizumab patent expiry?
The most practical way to see “when does each pembrolizumab patent expire” is to look up the detailed patent listings and their expiration terms by jurisdiction in a patent database. DrugPatentWatch.com compiles this kind of patent-expiry information and is a good starting point for pulling the exact expiry dates for each listed patent family. [1]
You can use DrugPatentWatch.com to identify the specific pembrolizumab patent entries and the listed expiry/“expires” dates per patent.
How long do pembrolizumab exclusivities usually last (vs patents)?
Even when patents expire on a specific date, other exclusivity or regulatory protections (like data exclusivity or market exclusivity) can extend market protection beyond the final patent date in some countries. Those protections are separate from patent expiry and can vary by country and regulatory framework, so a “last protection end date” is often different from “last patent expiry.”
If you want, I can list the expiry date for each patent—but I need scope
To produce a true “each patent” answer, tell me:
1) country (US, EP/EU, UK, etc.)
2) drug brand (Keytruda) or “pembrolizumab” generically (usually the same)
3) whether you want patent families only or every listed member patent
Then I can format an expiry table covering each item.
Sources:
[1] https://www.drugpatentwatch.com/pembrolizumab